Recall Register

Drug recall: Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA…

Class I FDA enforcement event 99603. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Class I, in the words of FDA

a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death

Fresenius Kabi USA, LLC started this drug recall on 10 Aug 2026. The firm address in the FDA record is in Lake Zurich, IL. FDA put the recall in Class I. FDA event 99603 has 1 product record. The first FDA enforcement report date is 2 Sep 2026. The record gives the status Ongoing. 79 of the 281 drug events that started in 2026 have more product records. The median drug event of 2026 has 1 product record.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA

Recalling firm

Fresenius Kabi USA, LLC, Lake Zurich, IL.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 99603: product records
Recall numberProductQuantityClassStatusReport date
D-0827-2026Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.4,643 20mL-vialsClass IOngoing2 Sep 2026

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class I: The highest of the three FDA recall classes.

The event in context

Drug events that started in 2026
281
Share of these events in Class I
10%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
67

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 99603. https://recallregister.com/fda/i/99603/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
10 Nov 2026
Newest FDA report date on the register
4 Nov 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA
What quantity of product is in FDA event 99603?
The FDA record gives this quantity: 4,643 20mL-vials
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2026 have the same class?
10% of the 281 drug events that started in 2026 are in Class I.